Table 1.
Clinical trials based on PLK1 inhibitors.
| NCT number | Phase | Disease | PLK1i | Ref |
|---|---|---|---|---|
| NCT02211859 | I | Advanced solid tumors | BI2536 | (127) |
| NCT02211872 | I | Advanced solid tumors | BI2536 | (128) |
| NCT00412880 | II | Small cell lung cancer | BI2536 | (129) |
| NCT01662505 | I | Acute myeloid leukaemia | BI6727 (Volasertib) | (130) |
| NCT00804856 | I/IIa | Acute myeloid leukaemia | BI6727 (Volasertib) | (131) |
| NCT01023958 | II | Urothelial cancer | BI6727 (Volasertib) | (132) |
| NCT00824408 | II | NSCLC | BI6727 (Volasertib) | (133) |
| NCT01014429 | I | Advanced solid tumors | NMS-1286937 (Onvansertib) | (134) |
| NCT00536835 | I | Advanced solid tumors | GSK461364 | (135) |
| NCT01179399 | I | Advanced solid tumors | TAK960 | Not yet published |
| NCT01538537 | I | Advanced solid tumors | ON01910 (Rigosertib) |
(136, 137) |
| NCT00854646 | I/II | Myelodysplastic syndrome Acute myeloid leukemia |
ON01910 (Rigosertib) |
(138) |
| NCT01168011 | I | Advanced solid tumors | ON01910 (Rigosertib) |
(139) |